Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash & Equivalents (2016 - 2025)

Vanda Pharmaceuticals' Cash & Equivalents history spans 16 years, with the latest figure at $84.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 17.07% year-over-year to $84.9 million; the TTM value through Dec 2025 reached $84.9 million, down 17.07%, while the annual FY2025 figure was $84.9 million, 17.07% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $84.9 million at Vanda Pharmaceuticals, down from $102.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $354.2 million in Q1 2023 and bottomed at $49.4 million in Q3 2022.
  • The 5-year median for Cash & Equivalents is $100.5 million (2024), against an average of $110.6 million.
  • The largest annual shift saw Cash & Equivalents surged 429.19% in 2023 before it plummeted 64.66% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $52.1 million in 2021, then soared by 159.32% to $135.0 million in 2022, then rose by 0.59% to $135.8 million in 2023, then fell by 24.67% to $102.3 million in 2024, then fell by 17.07% to $84.9 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Cash & Equivalents are $84.9 million (Q4 2025), $102.3 million (Q4 2024), and $100.5 million (Q3 2024).